Source: TUFTS UNIVERSITY submitted to NRP
IN VITRO TESTING OF COMPANY'S PROPRIETARY COMPOUND (SMECTA) IN C. DIFFICILE ASSAYS
Sponsoring Institution
Cooperating Schools of Veterinary Medicine
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
0225414
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Jun 17, 2010
Project End Date
Jul 31, 2012
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
TUFTS UNIVERSITY
200 WESTBORO ROAD
N. GRAFTON,MA 01536
Performing Department
Infectious Disease and Global Health
Non Technical Summary
Clostridium difficile is a pathogen causing pseudomembranous colitis, which accounts for a quarter of all cases of antibiotic-associated diarrhea. The incidence of C. difficile infection (CDI) has increased significantly in both North America and Europe, causing lengthy hospitalization, substantial morbidity and mortality.
Animal Health Component
(N/A)
Research Effort Categories
Basic
(N/A)
Applied
(N/A)
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
72240101150100%
Knowledge Area
722 - Zoonotic Diseases and Parasites Affecting Humans;

Subject Of Investigation
4010 - Bacteria;

Field Of Science
1150 - Toxicology;
Goals / Objectives
The purpose of this study is to conduct in vitro testing of the drug Diosmectite in C. difficile assays. The specific aims are to: 1) Determine the toxin-binding activities. 2) Determine the binding affinity. 3) Determine the neutralizing / blocking effects. 4) Determine the effects on antibiotics.
Project Methods
Ad 1): use culture supernatants from laboratory and epidemic strains. ELISA to measure toxins. Neutralizing assay to measure biological activities (turnaround time 8-11 days). Ad 2): use purified TcdA and TcdB (turnaround time 3-5 days). Ad 3): on polarized monolayers using transwell system (turnaround time 21-25 days). Ad 4: metronidazole and vancomycin (turnaround time 8-11 days).